摘要
背景与目的：目前认为紫杉醇、顺铂（DDP）对晚期胃癌疗效肯定，毒副反应可以耐受。且近年来大量研究证实腹腔热灌注化疗对消化道癌有确切临床疗效。本研究目的为评价紫杉醇周方案给药联合顺铂腹腔热灌注化疗治疗晚期胃癌的近期疗效与毒副反应。方法：51例晚期胃癌患者随机分为全身化疗组（25例），用紫杉醇70mg／m^2，iv，每周1次，共8周，DDP25mg／m^2，iv，第1—3天，每3周重复，共用4个周期；联合腹腔热灌注化疗（CHPP）组（26例），紫杉醇给药方法同前，DDP60mg／m^2，CHPP，第1、8、22、29天，该组患者化疗期间均予腹部热疗2次／周。结果：有效率（CR＋PR）、临床受益率（CBR）联合CHPP组分别为65．4％，92．3％，全身化疗组为36．0％，68．0％，差异有显著性（P〈0．05）；疾病进展时间及中位生存期联合化疗组分别为6．9个月，12．1个月，全身化疗组为5．6个月，10．8个月，差异无显著性（P〉0．05）；主要不良反应为骨髓抑制、恶心／呕吐，两组各项不良反应差异无显著性。结论：紫杉醇周方案给药联合顺铂腹腔热灌注化疗治疗晚期胃癌近期疗效好，不良反应可以耐受，值得进一步研究。
Background and purpose： Paclitaxel and cisplatin were demonstrated to be effective and well-tolerated for advanced gastric cancer. The clinical efficacy of hyperthermic intraperitoneal perfusion （CHPP） has been established in numerous studies in recent years. The purpose of the study was to evaluate the efficacy and toxicities of paclitaxel combined with CHPP with cisplatin in the treatment of patients with advanced gastric cancer. Methods： 51 patients with advanced gastric cancer were randomized into systemic chemotherapy group（ 25 patients） who received paclitaxel 70 mg/m^2, iv, 1/wk × 8wk, DDP 25 mg/m^2, iv, d1-3, reapeated every 3 weeks for 4 cycles and systematic plus CHPP group（ 26 patients） who received paclitaxel 70 mg/m^2, iv, 1/wk × 8wk, DDP 60 mg/m^2, CHPP, dl, 8, 22, 29, and abdomen hyperthermia treatment twice a week in the whole chemotherapy period. Results： The response rate （ CR ＋ PR） , the clinical benefitial response （CBR） in systematic plus CHPP group were 65.4% and 92.3% , and those in systemic chemotherapy group were 36.0% and 68.0%. There was obviously a statistical difference between two groups（ P 〈 0.05） ; The median TTP and MST were 6.9 month and 12.1 months in systematic plus CHPP group, 5.6 month and 10.8 months in systemic chemotherapy group. There was no obvious statistical difference between the two groups（ P 〉 0.05）. The major toxicities were myelo-suppression and nausea/vomiting. There was no significant difference in side-effect between the two groups. Conclusions： Paclitaxel administered by weekly infusion combined with hyperthermic intraperitoneal perfusion chemotheraphy with cisplatin in the treatment of advanced gastric cancer is effective and tolerable. It is worth studying in the future.
出处
《中国癌症杂志》
CAS
CSCD
2007年第2期147-150,共4页
China Oncology
关键词
晚期胃癌
紫杉醇
顺铂
腹腔温热灌注化疗
advanced gastric carcinoma
paclitaxel
cisplatin
hyperthermic intraperitoneal perfusion chemotheraphy
